Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Study limitation reported by the research below: “Sample size for the OPTIMUM arm (n=107) is modest for subset analyses; results in smaller subgroups (e.g., plasma cell leukaemia) may be underpowered.”